EUVIMEDEUVIMED entdecken
Multizentrische StudieVergleichsstudieOpen Access · CC BY-NC 4.0

Comparing Long‐Term Infliximab Persistence Following a Switch to a Biosimilar in Patients With Inflammatory Bowel Disease: No Cause for Concern

Paulina Suo, Ashish Srinivasan, Lena Thin, Yoon-Kyo An, Richard G Fernandes, Simon Ghaly, Angus W Jeffrey, Shankar Menon, Nicholas Olsen, Thomas Skinner iD, Daniel R van Langenberg iD, James Winston und 1 weitere

Journal of Gastroenterology and Hepatology · 2025

DOI: 10.1111/jgh.16916 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Gastroenterology and Hepatology, 2025. Verfasst von Paulina Suo und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia. Hauptthemen laut MEDLINE: Infliximab, Biosimilar Pharmaceuticals, Inflammatory Bowel Diseases, Drug Substitution. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Several studies have demonstrated that switching stable patients with inflammatory bowel disease (IBD) from originator to biosimilar infliximab is noninferior to continuing originator infliximab. However, “real‐world” data comparing long‐term outcomes between switch and nonswitch cohorts is lacking. This study aimed to address this gap by comparing long‐term outcomes in IBD patients across switch and nonswitch cohorts.

Methods

The SAME study was a multicenter, prospective parallel cohort noninferiority study, that enrolled Australian IBD patients in steroid‐free clinical remission on maintenance originator infliximab, who either continued originator infliximab ( n = 141) or switched to biosimilar (CT‐P13) infliximab ( n = 204). Here, we present long‐term outcomes, with treatment persistence beyond 48 weeks as the primary outcome. Disease worsening, defined as any of infliximab discontinuation, dose escalation, antibody development, or adverse event, were secondary outcomes of interest.

Results

Of 345 patients enrolled in the SAME study, 320 (92.7%) patients were followed up beyond 48 weeks (median: 54.2 months [IQR 46.1–59.3]). There were no differences in infliximab discontinuation between switch and nonswitch cohorts (35.3% vs. 37.6%, p = 0.47). Infliximab discontinuation due to disease worsening (21.7% vs. 23.6%), dose escalation (35.2% vs. 32.4%), antibody development (5.3% vs. 11.3%), and infliximab‐related adverse events (7.8% vs. 8.3%), were also comparable (all p > 0.70) between switch and nonswitch cohorts.

Conclusions

Long‐term infliximab persistence was similar between switch and nonswitch cohorts over 4 years of follow‐up. These data represent the longest duration of “real‐world” follow‐up, and should provide further reassurance that nonmedical switching is safe and clinically comparable to ongoing originator infliximab in clinically stable patients with IBD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

InfliximabBiosimilar PharmaceuticalsInflammatory Bowel DiseasesDrug SubstitutionGastrointestinal AgentsAntibodies, MonoclonalHumansMaleFemaleAdultProspective StudiesTime FactorsTreatment OutcomeMiddle AgedAustraliaFollow-Up Studies

Stichwörter der Autor:innen

IBDclinical intestinal disordersclinical trialsgastroenterologypharmacokinetics

Substanzen

InfliximabBiosimilar PharmaceuticalsCT-P13Gastrointestinal AgentsAntibodies, Monoclonal

Autor:innen und Institutionen

  • Department of Gastroenterology, St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia.
  • School of Clinical Medicine, University of New South Wales, New South Wales, Australia.
  • Department of Gastroenterology, Eastern Health, Melbourne, Australia.
  • Eastern Health Clinical School, Monash University, Melbourne, Australia.
  • Department of Gastroenterology, Fiona Stanley Hospital, Perth, Australia.
  • Department of Medicine, University of Western Australia, Perth, Australia.

ORCID-Profile: Thomas Skinner, Daniel R van Langenberg, Craig Haifer

Zitieren

APA

Suo, P., Srinivasan, A., Thin, L., An, Y. K., Fernandes, R. G., Ghaly, S., Jeffrey, A. W., Menon, S., Olsen, N., Skinner, T., van Langenberg, D. R., Winston, J., & Haifer, C. (2025). Comparing Long‐Term Infliximab Persistence Following a Switch to a Biosimilar in Patients With Inflammatory Bowel Disease: No Cause for Concern. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.16916

Vancouver

Suo P, Srinivasan A, Thin L, An YK, Fernandes RG, Ghaly S, et al. Comparing Long‐Term Infliximab Persistence Following a Switch to a Biosimilar in Patients With Inflammatory Bowel Disease: No Cause for Concern. Journal of Gastroenterology and Hepatology. 2025. doi:10.1111/jgh.16916

BibTeX
@article{Suo2025,
  author = {Suo, Paulina and Srinivasan, Ashish and Thin, Lena and An, Yoon-Kyo and Fernandes, Richard G and Ghaly, Simon and Jeffrey, Angus W and Menon, Shankar and Olsen, Nicholas and Skinner, Thomas and van Langenberg, Daniel R and Winston, James and Haifer, Craig},
  title = {Comparing Long‐Term Infliximab Persistence Following a Switch to a Biosimilar in Patients With Inflammatory Bowel Disease: No Cause for Concern},
  journal = {Journal of Gastroenterology and Hepatology},
  year = {2025},
  doi = {10.1111/jgh.16916}
}
Kostenlos starten →